![Getting beyond the immunotherapy divide: a call to action](https://cdn.cancerletter.com/media/2019/05/divide-web.jpg)
![Getting beyond the immunotherapy divide: a call to action](https://cdn.cancerletter.com/media/2019/05/divide-web.jpg)
Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
In Brief
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission